 | |
| Discipline | Oncology |
|---|---|
| Language | English |
| Edited by | Antoinette Wozniak, MD |
| Publication details | |
| History | 1999–present |
| Publisher | |
| 4.2 (2017) | |
| Standard abbreviations | |
| ISO 4 | Clin. Lung Cancer |
| Indexing | |
| ISSN | 1525-7304 |
| Links | |
Clinical Lung Cancer is a peer-reviewed medical journal that has been published by Elsevier since 2011. It was established by the CIG Media Group in 1999.
Clinical Lung Cancer is indexed in Index Medicus/PubMed, EMBASE (Excerpta Medica), Current Contents/Clinical Medicine, Science Citation Index Expanded, CINAHL , and Chemical Abstracts. It is published six times annually.
Clinical Lung Cancer publishes articles on detection, diagnosis, prevention, and treatment of lung cancer. The emphasis is on recent scientific developments in all areas related to lung cancer.
Areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
The journal publishes editorials, original research papers, comprehensive reviews, current treatment reports, case reports, brief communications, current trials, translational medicine pieces, and a "Meeting Highlights" section.
The editor-in-chief is David R. Gandara. He is a member of the board of directors of the International Association for the Study of Lung Cancer and the Addario Foundation. He served as a member of the board of directors of the American Society of Clinical Oncology (ASCO) and as secretary-treasurer. Gandara is a member of professional committees, including the NCI Investigational Drug Steering Committee and the NCI Science Correlates Committee.
He is the Chair of the Southwest Oncology Group's Lung Committee (SWOG). Gandara has published more than 225 articles and 10 book chapters. Gandara holds a BA from the University of Texas and an MD with honors from the University of Texas Medical Branch.
Vincent Theodore DeVita Jr. is the Amy and Joseph Perella Professor of Medicine at Yale Cancer Center, and a Professor of Epidemiology and Public Health. He directed the Yale Cancer Center from 1993 to 2003. He has been president of the American Cancer Society (2012-2013). He is internationally recognized as a pioneer in the field of oncology for his work on combination-chemotherapy treatments.
The European Organisation for Research and Treatment of Cancer (EORTC) is a unique pan-European non-profit clinical cancer research organisation established in 1962 operating as an international association under Belgium law. It develops, conducts, coordinates and stimulates high-quality translational and clinical trial research to improve the survival and quality of life of cancer patients. This is achieved through the development of new drugs and other innovative approaches, and the testing of more effective therapeutic strategies, using currently approved drugs, surgery and/or radiotherapy in clinical trials conducted under the auspices of a vast network of clinical cancer researchers supported by 220 staff members based in Brussels. The EORTC has the expertise to conduct large and complex trials especially specific populations such as the older patient and rare tumours.
Cancer and Leukemia Group B is a cancer research cooperative group in the United States.
John Gordon McVie was an international authority on the treatment and research of cancer. He wrote over 350 peer-reviewed articles, editorials and books. McVie was born in Glasgow, Scotland and died of non-Hodgkin lymphona and COVID-19 in Bristol, England.
William S. Dalton is an American physician and oncologist, who is board certified in internal medicine and oncology. Since 2002 he has been the President, CEO, and Center Director of the H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida (USF). He served as dean of the University of Arizona College of Medicine, 2001-2002.
Clinical Colorectal Cancer is a peer-reviewed medical journal published by CIG Media Group from 2001 to 2010 and by Elsevier since 2011. It publishes original articles describing various aspects of clinical and translational research of gastrointestinal cancers. The journal is devoted to articles on detection, diagnosis, prevention, and treatment of colorectal, pancreatic, liver, and other gastrointestinal cancers. The main emphasis is on recent scientific developments in all areas related to gastrointestinal cancers. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
Hydrazine sulfate, more properly hydrazinium hydrogensulfate, is a salt of the cation hydrazinium and the anion bisulfate (hydrogensulfate), with the formula N2H6SO4 or more properly [N2H5]+[HSO4]−. It is a white, water-soluble solid at room temperature.
Clinical Cancer Research is a peer-reviewed medical journal on oncology, including the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer, medical and hematological oncology, radiation therapy, pediatric oncology, pathology, surgical oncology, and clinical genetics. The applications of the disciplines of pharmacology, immunology, cell biology, and molecular genetics to intervention in human cancer are also included. One of the main interests of Clinical Cancer Research is on clinical trials that evaluate new treatments together with research on pharmacology and molecular alterations or biomarkers that predict response or resistance to treatment. Another priority for Clinical Cancer Research is laboratory and animal studies of new drugs as well as molecule-targeted agents with the potential to lead to clinical trials, and studies of targetable mechanisms of oncogenesis, progression of the malignant phenotype, and metastatic disease. The journal is published by the American Association for Cancer Research.
The Journal of the National Cancer Institute (JNCI) is a peer-reviewed medical journal covering research in oncology that was established in August 1940. It is published monthly by Oxford University Press and is edited by Patricia A. Ganz. It was merged with Cancer Treatment Reports in January 1988. JNCI used to be the official journal of the National Cancer Institute (NCI); however, in 1996, the NCI and JNCI agreed to grow apart. Over the next five years, JNCI became independent of the NCI.
Robert E. Wittes was Physician-in-Chief of Memorial Sloan-Kettering Cancer Center, from 2002 until December 31, 2012. Prior to his appointment at MSKCC, he was Deputy Director for Extramural Sciences and Director of the Division of Cancer Treatment and Diagnosis at the National Cancer Institute, where he oversaw NCI's extramural clinical and basic research programs, including the evaluation of new therapeutics, diagnostics, and translational research. Wittes is a fellow of the American College of Physicians, a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the American Federation for Medical Research. In addition to his institutional affiliations, Dr. Wittes has served as editor-in-chief of the Journal of the National Cancer Institute and Oncology. He has served on the editorial boards of Clinical Cancer Research, Current Opinion in Oncology, The American Journal of Clinical Oncology; Cancer Investigation, and The International Journal of Radiation Oncology-Biology & Physics, among others.
Otis Webb Brawley is an American physician and the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University. He served as Chief Medical and Scientific Officer and Executive Vice President of the American Cancer Society from July 2007 to November 2018. He is board certified in internal medicine and medical oncology and is a Master of the American College of Physicians, Fellow of the American Society of Clinical Oncology, and a Fellow of the American College of Epidemiology. He is a member of the Institute of Medicine now known as the National Academy of Medicine.
William Douglas Figg is an American scientist (pharmacologist). He is a senior investigator (tenured) at the National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland. He holds multiple titles within the NCI: Associate Director of the Center for Cancer Research, Co-Director of the Office of Translational Resources, Acting Branch Chief for the Genitourinary Malignancies Branch, Chief of the Clinical Pharmacology Program, and head of the Molecular Pharmacology Section. Dr. Figg is also the Co-Chief of Basic Research at the Center for Prostate Disease Research within the Walter Reed National Military Medical Center – Murtha Cancer Center in Bethesda, Maryland.
Professor Minesh P. Mehta, MD, FASTRO, is an American radiation oncologist and physician-scientist of Indian origin, Ugandan birth, Zambian Schooling and American Training, who contributed to the field of oncology for more than two and half decades.
Eric P. Winer is a medical oncologist and clinical researcher specializing in breast cancer. He is director of Yale Cancer Center and physician-in-chief of Smilow Cancer Hospital at Yale New Haven, effective February 1, 2022. From 1997 to 2021, he was the Chief of the Breast Oncology Program at Dana–Farber Cancer Institute in Boston, Massachusetts. Beginning in 2013, he held a range of institutional roles at Dana-Farber, including Chief of Clinical Development, the Thompson Chair in Breast Cancer Research and Director of the Dana-Farber/Harvard SPORE in Breast Cancer. He also served as a Professor of Medicine at Harvard Medical School. He is currently the president of the American Society of Clinical Oncology. His career has been focused on breast cancer treatment and research.
Waun Ki Hong was Professor of Medicine at The University of Texas MD Anderson Cancer Center, where he served as chairman of the Department of Thoracic/Head & Neck Medical Oncology from 1993 to 2005 and as head of the Division of Cancer Medicine from 2001 to 2014. He was also an American Cancer Society Professor and the Samsung Distinguished University Chair in Cancer Medicine emeritus.
Thomas E. Hutson is an American medical oncologist and cancer researcher based in Dallas, Texas. He is the director of Genitourinary Oncology Program and co-director of the Urologic Cancer Research and Treatment Center at Baylor University Medical Center. He is a Professor of Medicine at the Texas A&M Health Science Center College of Medicine and serves as a chair of Genitourinary Research for US Oncology and McKesson.
Elizabeth M. Jaffee is an American oncologist specializing in pancreatic cancer and immunotherapy.
Oliver Sartor is an American oncologist and research scientist. He is currently the assistant dean for oncology and the C.E. and Bernadine Laborde Professor of Cancer Research, Medicine and Urology Departments at the Tulane School of Medicine in New Orleans, Louisiana. His research has mainly focused on translational science and clinical research trials of advanced prostate cancer since 1990 and he is recognized as an expert in that field through his contributions to the practice and the publishing of over 500 peer-reviewed articles and numerous book chapters and reviews. Sartor also serves as the editor-in-chief of the bimonthly journal Clinical Genitourinary Cancer that mainly focuses on research in genitourinary oncology.
Deborah Watkins Bruner is an American researcher, clinical trialist, and academic. She is the senior vice president for research at Emory University. Her research focus is on patient reported outcomes, symptom management across cancer sites, sexuality after cancer treatment, and effectiveness of radiotherapy modalities. Bruner's research has been continually funding since 1998, with total funding of her research exceeding $180 million. She is ranked among the top five percent of all National Institutes of Health-funded investigators worldwide since 2012, according to the Blue Ridge Institute for Medical Research.
